drugset / Trial / NCT02873416
Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Lung Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the safety and effectiveness of cell therapy using Precision Cell Immunotherapy to treat Advanced Lung Cancer. Eligibility: Individuals greater than or equal to 18 years of age and less than or equal to 65 years of age who have been diagnosed with Advanced Lung Cancer.
Timeline
- Start
- 2016-08
- Primary completion
- 2018-03
- Completion
- 2018-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DC cell suspension | Cell therapy | 1 ml | Subcutaneous |
| Subject | DC cell suspension | Cell therapy | 1e+07 cells | Subcutaneous |
| Subject | PNAT | Cell therapy | 300 ml | Intravenous |
| Subject | PNAT | Cell therapy | 1e+09 cells | Intravenous |
| Subject | PNAT | Cell therapy | 6e+09 cells | Intravenous |
| Background | Cisplatin | Other / unclassified | 60 mg/m2 | Intravenous |
| Background | Gemcitabine | Small molecule | 1 g | Intravenous |